Theradiag: Report of the Ordinary and Extraordinary General Meeting of 5 May 2022
06 Maggio 2022 - 7:30AM
Business Wire
- New terms of office for Mr Pierre MORGON as Director and
Chairman of the Board of directors
- Appointment of Mr Larry ABENSUR, Mr Thomas LAMY and Mr
Thierry PAPER as new directors
Regulatory News:
THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company
specializing in in vitro diagnostics and theranostics, announces
that the ordinary and extraordinary general meeting held today was
able to validly deliberate, as the quorum was reached.
The shareholders of the Company adopted all the resolutions of
the ordinary and extraordinary general meeting, except for
resolutions nb. 5, 7, 8, 9 and 21. In particular, the ordinary
general meeting appointed Mr Pierre Morgon for a new term of office
as director and appointed Mr Larry Abensur, Mr Thomas Lamy and Mr
Thierry Paper as directors.
Following this general meeting, the Board of directors, now
composed of four members, met and appointed Mr Pierre Morgon as
Chairman of the Board of directors.
All the results of the votes on the resolutions will be
available to the public in the presentation of the general meeting
of May 5, 2022 available on Theradiag's website in the General
Meetings section. The minutes of the meeting will also be
available within the legal deadlines in the General Meetings
section.
Financial calendar:
- H1 2022 revenue, Monday July 18, 2022
- H1 2022 results, Monday September 19, 2022
About Theradiag
Theradiag is the market leader in biotherapy monitoring.
Capitalizing on its expertise in the diagnostics market, the
Company has been developing, manufacturing and marketing innovative
in vitro diagnostic (IVD) tests for over 30 years.
Theradiag pioneered “theranostics” testing (combining therapy
with diagnosis), which measures the efficacy of biotherapy in the
treatment of chronic inflammatory diseases. Going beyond mere
diagnosis, Theranostics aims to help clinicians set up “customized
treatment” for each patient. This method favors the
individualization of treatment, evaluation of its efficacy and the
prevention of drug resistance. In response to this challenge,
Theradiag develops and markets the CE-marked TRACKER® range, a
comprehensive solution of inestimable medical value.
The Company is based in Marne-la-Vallée, near Paris, has
operations in over 70 countries and employs over 60 people. In
2021, the Company posted revenue of €11.1 million. The Theradiag
share is listed on Euronext Growth Paris (ISIN: FR0004197747) and
is eligible for the French PEA-PME personal equity plan. For more
information about Theradiag, please visit our website:
https://www.theradiag.com/
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220505006206/en/
Theradiag Bertrand de Castelnau CEO/Managing
Director +33 (0)1 64 62 10 12 contact@theradiag.com
NewCap Financial Communications & Investor Relations
Pierre Laurent / Quentin Massé +33 (0)1 44 71 94 94
theradiag@newcap.eu
NewCap Media Relations Nicolas Mérigeau +33 (0)1
44 71 94 98 nmerigeau@newcap.fr
Grafico Azioni Theradiag (EU:ALTER)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Theradiag (EU:ALTER)
Storico
Da Apr 2023 a Apr 2024